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                                  1. INTRODUCTION 
1.1 Definition 
Urolithiasis: It is a consequence of complex physical processes. The major factors are
super saturation of urine with the offending salt and crystallization. Crystals retained
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in  kidney  can  become  nucleus  for  stone  formation.  This  process  is  known  as
Urolithiasis or nephrolithiasis. 
1.2 Classification of renal stones 
Urolithiasis  or  the renal  stones  which are formed in  the kidneys of  various  forms
based on their chemical composition and their structures over 90 % of stones contain
uric acid, urates, oxalate or phosphates, the last two being most commonly found. Based
on the predominant chemical composition, Urolithiasis are classified as
1.2.1. Calcium containing stones 
     a. Calcium oxalate stones (CaOx)
     b. Calcium phosphate stones (CaPh)
1.2.2. Uric acid stones
1.2.3. Struvite stones
1.2.4. Cystine stones and miscellaneous stones1-2
1.2.1 Calcium containing stones 
Calcium stones are the most common type of kidney stones, accounting for about 70%
to 75% of stones. The highest incidence of calcium urolithiasis is between ages of 30
and 50 calcium stones either are composed entirely of CaOx or have a small core of
CaPh. The presence of a small amount of CaPh has no implications for pathogenesis
or management.  
1.2.1.a Calcium oxalate stones 
CaOx in pure form or in combination with CaPh is the most common component of
urinary stones.  It  generally varies  from 4-8 mm in  size.  The commonest  form of
oxalate is as calcium oxalate, mainly calcium oxalate monohydrate [Ca (COO)2, H2O],
but some calcium oxalate di hydrate crystals [Ca(COO)2, 2H2O] may also be present.
Oxalate stones are among the hardest found and so are not easily crushed. 
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Idiopathic hypercalciuria: Hypercalciuria in the presence of normal serum calcium
is termed  idiopathic hypercalciuria. The various causes of idiopathic hypercalciuria
are as follows: 
 Absorptive hypercalciuria:  The primary defect in absorptive hypercalciuria,
inherited  as  an  autosomal  dominant  trait,  is  increased  passive  mucosal
absorption of calcium and oxalate in the jejunum. 
 Renal hypercalciuria: In renal hypercalciuria, the underlying abnormality is a
primary renal  wasting of  calcium.  Urinary losses  of  calcium reduce  serum
calcium levels and cause a secondary elevation in parathyroid hormone (PTH).
This  results  in  1,  25-dihydroxy-vitamin  D  production  and  an  increase  in
intestinal calcium absorption. 
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Resorptive hypercalciuria:  The condition that results in hypercalciuria is increased
bone resorption, usually caused by subtle hyperparathyroidism. These patients have
parathyroid adenomas but do not have impressive hypercalcemia. 
Primary hyperparathyroidism: Primary hyperparathyroidism is caused by a PTH-
secreting adenoma of the parathyroid glands.  PTH increases serum calcium by the
following mechanisms: 
1. PTH stimulates osteoclasts to demineralize bone by breaking down the bone crystal
apatite. The dissolution of apatite results in the release of calcium and phosphate into
the blood stream. 
2. PTH causes calcium resorption by the kidneys and decreases renal absorption of
phosphates. 
3. PTH stimulates production of 1, 25-dihydroxy vitamin D3 by the kidneys, which in
turn increases intestinal resorption of calcium. PTH does not seem to have an effect on
intestinal calcium absorption. 
Hypercalcemia  causes  hypercalciuria,  which  predisposes  to  urinary  calcium  stone
formation. Decreased urinary citrate has been seen in hyper parathyroid patients. 
Hypercalcemia  of  non  parathyroid  origin: Common  causes  of  hypercalcemia-
causing  urinary  stone  disease,  include  granulomatous  diseases,  hyperthyroidism,
glucocorticoid-induced  hypercalcemia,  pheochromocytoma,  immobilization  and
thiazide  diuretics.  These  can be distinguished  from hyperparathyroidism by serum
parathyroid hormone levels. Serum PTH is elevated in primary hyperparathyroidism,
whereas it is generally lower in other hyper calcemias. 
Low  urinary  citrate: Citrate  complexes  urinary  calcium  and  reduces  its  ionic
concentration. It inhibits spontaneous and heterogeneous nucleation of CaOx crystal.
Citrate restores the inhibitory activity of Tomm-Horsfall protein. The most important
cause of hypocitraturia is metabolic acidosis, which causes increased proximal tubular
reabsorption  of  citrate.  Hypocitraturia  is  seen  in  15%  to  63%  of  patients  with
urolithiasis. 
Hyperoxaluria: Oxalate is the anion most frequently associated with calcium in the
precipitation  of  salts  leading  to  crystal  formation,  growth,  retention  and  stone
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formation. 80 % of  urinary oxalate is endogenous in origin and 10% is dietary in
origin.  Hyperoxaluria  results  from  various  factors  like  diet,  genetic  predisposure,
intestinal diseases and others.
 Dietary hyperoxaluria: Normal people excrete 20 – 40 mg (222 - 444 µmol)
of oxalate. A reasonable upper limit of excretion is 45 mg (500µmol) daily for
men and 40 mg for women. A simple dietary excess of oxalate of 50- 60 mg
(556-667µmol) is possible from foods such as spinach, rhubarb, Swiss chard,
cocoa, beets, peppers, wheat germ, pecans, peanuts, okra, chocolate and lime
peel. This type of hyperoxaluria is frequently observed in nephrolithiasis.
 Primary hyperoxaluria: Two genetic disorders lead to hyperoxaluria. Type I
primary  oxaluria,  an  autosomal  recessive  trait  is  caused  by  molecular
abnormalities that reduce the activity of hepatic peroxisomal enzyme alanine:
glyoxylate aminotransferase, thereby increasing the availability of glyoxylate,
which is irreversibly converted to oxalic acid. Type II primary hyperoxaluria or
L-glyceric aciduria is a much rare variant caused by deficiencies of hepatic
enzymes D-glycerate dehydrogenase and glyoxylate reductase, which causes
an increase in urinary oxalate (135- 270 mg ) and glycerate excretion.
Enteric  hyperoxaluria:  Occurs  in  patients  with  short  bowel  syndrome  or
malabsorption. The pathogenesis is exposure of the colonic mucosa to detergents in
the form of bile salts and fatty acids which nonselectively increases the permeability
to  numerous  molecules  including  oxalate.  Hyperoxaluria  causes  oxalate  crystal
formation, which combines with urinary calcium to form CaOx stones.
Hyperuricosuria: Excessive dietary intake of purine is the most common cause of
hyperuricosuria. An abnormality in the renal handling of urate is seen in such patients.
Uric  acid  promotes  CaOx  crystallization  by  facilitating  the  formation  of  nuclei.
Sodium hydrogen urate and uric acid crystals can initiate CaOx crystal formation in
seeded solution; however, sodium hydrogen urate crystals are not seen in fresh urine
or kidney stones. 
1.2.1.b Calcium phosphate stones 
Calcium phosphate stones occur only when the chemical pressure for crystallization is
high  and  thus  they  are  usually  seen  in  very  active  stone  disease.  Pure  Calcium
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phosphate  stones  are  almost  always  associated  with  the  renal  tubular  acidification
defects. When the kidneys lose some of their ability to lower urinary pH, the resulting
higher  pH  increases  the  divalent  and  trivalent  forms  of  phosphate,  which  causes
Calcium phosphate supersaturation3-4.
1.2.2 Uric acid stones 
Uric acid calculi account for 5 to 10 % of all stones. The principal cause of uric acid
crystallization is the super saturation of urine with respect to un dissociated uric acid.
The most important risk factor is acid urine, with the pH persistently below 6.0 and
also infections of urinary tract. 
1.2.3 Struvite stones 
Struvite stones are composed of magnesium, ammonium and phosphate mixed with
carbonate.  These  stones  are  formed  in  urine  with  a  pH  of  greater  than  7.2  and
ammonia in the urine, produced by urease-producing bacteria. Urease hydrolyzes urea
into ammonia and carbon dioxide. The ammonia formed combines with hydrogen to
form ammonium. The carbon  dioxide  formed is  hydrated  to  carbonic  acid,  which
dissociates to bicarbonate ion and a proton. The reaction is illustrated as follows: 
NH2CONH2 + H2O ↔ 2 NH3 + CO2
2 NH3 + H2O ↔ 2 NH4+ + OH¯
CO2 + H2O ↔ H+ + HCO3 ↔ H+ + CO32¯
The responsible bacteria include Proteus species, Klebsiella, Serratia, enterobacteria,
Pseudomonas  and  Staphylococci.  Amongst  these,  Proteus  mirabilis  is  the  most
common organism associated with struvite calculi. The other mechanism by which
bacterial  infection  can  induce  stone  formation  is  by  increased  crystal  adherence.
Ammonia damages the glycosaminoglycan layer lining of the bladder mucosa, which
in turn increases the adherence of struvite crystals in the bladder5. 
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1.2.4 Cystine stones 
Cystine stones account for less than 5 % of all calculi and occur only in patients with
cystinuria.  Cystinuria  is  an autosomal recessive disorder  of  transmembrane cystine
transport manifested in the intestine and in the kidneys6. 
1.3 Causes of renal stone formation 
In  majority of patients  more than one abnormal  stone risk factors are involved. It
include  a  mixture  of  metabolic  and  environmental  factors  like  gout,  renal  tubular
acidosis, hypocitraturia, hyperoxaluria, hyperparathyroidism, urinary tract infections,
cystinuria  and  hyperuricosuric  hypercalciuria  are  contributory  factors  for  the
formation of urinary stones. 
1.4 Mechanism of stone formation 
1.4.1 Physical concepts 
The major  factors  of  urolithiasis  are  supersaturation and crystallization,  inhibitors,
complexors, promoters and matrix. The sequence of events leading to stone formation
is as follows: 
                        Fig 2: Mechanism of stone formation
 Saturation, Supersaturation and Thermodynamic Solubility Product
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1.4.2 Pathogenesis of stone formation 
Renal stone formation requires that stone forming crystalloids in urine come out of
solution. Because crystalloids in solution are in equilibrium with crystalloids in the
solid  phase,  a  minimum  condition  is  that  urine  be  supersaturated  with  relevant
crystalloids. This condition is often met: many healthy persons, probably the majority,
have concentrations of calcium and oxalate in urine such that their activity product
exceeds the solubility threshold (i.e. urine is supersaturated with these crystalloids).
But urine has a strong inhibitory action that prevents crystallization and other stone
forming processes. Three processes promote stone formation: 
 Nucleation,
  Aggregation, and
  Crystal growth. 
Nucleation: 
Nucleation  involves  the  association  of  crystalloids  in  solution  (e.g.  calcium  and
oxalate) to form a sub microscopic particle of about 100 atoms. The process requires
energy and is facilitated when an external surface can serve as a lattice or anchor,
thereby  lowering  the  free  energy  requirement.  Such  a  surface  is  provided  by
microscopic uric acid moieties, which function as promoters of CaOx stone formation.
 Homogeneous nucleation:  The process by which the earliest crystal nuclei
form in  pure  solutions  is  called  homogeneous  nucleation.  It  occurs  in  the
absence of a surface or lattice. 
 Heterogeneous  nucleation:  In  this  process  the  nuclei  usually  form  on
existing  surfaces.  Epithelial  cells,  urinary casts,  red  blood  cells  and  other
crystals can act as nucleating foci in urine. 
Aggregation 
Aggregation is the process by which nuclei or larger structures adhere to one another.
The  initial  nuclei  can  grow  by  the  precipitation  of  additional  salt  on  the  lattice
framework. It takes between 5 and 7 min for urine to flow from the glomerulus to the
collecting duct. The earliest site of stone formation in human is the papillary duct or
the collecting tubule, where the diameter is 50 to 200 µm .Once nuclei are formed they
bounce  apart  from each  other,  float  freely and  become kinetically  active.  If  they
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remain independent and float freely, they are washed away by urine flow. However,
under certain circumstances, these nuclei come in close contact and due to chemical or
electrical forces can bind to each other, a process called crystal aggregation. 
Crystal growth 
A third  process  is  crystal  growth,  in  which  crystalloids  come  out  of  solution  to
associate  with  the  solid  phase  of  growing  crystal  in  a  geometrically  precise
arrangement. The combination of crystal aggregation and crystal growth can explain
the genesis of urinary calculi. Another process that may lead to CaOx stone formation
is crystal retention. In most instances, crystal aggregates are too fragile to occlude the
collecting duct long enough to give rise to a stone7-8.
1.4.3 Promoters, inhibitors and complexing agents: 
Each  process  of  stone  formation  has  specific  promoters  and  inhibitors.
Glycosaminoglycans  promote  crystal  nucleation  but  inhibit  crystal  aggregation.
Tamm- Horsfall protein, a product of the thick ascending limb of Henle, may act as a
promoter or inhibitor of crystal formation depending on its state of aggregation. 
Nucleation  of  CaOx  is  inhibited  by  magnesium  and  citrate,  which  forms  soluble
complexes with calcium and so reduces its effective concentration. a highly negatively
charged  molecule  rich  in  aspartate  and  γ-carboxyglutamic  acid  residues,  is  potent
inhibitor  of  CaOx  crystallization  in  simple  solutions.  Aggregation  is  inhibited  by
uropontin  is  an  aspartic  acid-rich  protein  that  shares  the  N-terminal  amino  acid
sequences  with  human  osteopontin.  It  is  an  important  inhibitor  of  CaOx  crystal
growth. Citrate is a potent complexor of calcium and reduces the ionic calcium in the
urine with consequent reduction in the supersaturation of calcium salt. Citrate exerts
maximum effect at a pH of 6.5. Magnesium, a divalent cation, complexes oxalate in
the CaOx system7.
1.5 Signs and symptoms 
Kidney stones on accumulation in the urinary tract exhibit specific symptoms and the
most specific one is severe pain in the. The common symptoms include, back pain on
one or both sides,  Progressive severe colicky (spasm-like) may radiate or move to
lower in flank, pelvis, groin, genitals, Nausea, vomiting, Urinary frequency/urgency,
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increased (persistent urge to urinate), Blood in the urine , Abdominal pain, Testicle
pain , Fever, Chills and Abnormal urine color8
1.6 Diagnosis (Investigations)
A. Urine analysis: Urine analysis in most patients with ureteral calculi reveals the
presence of microscopic or gross hematuria. A urine analysis should be done promptly
after  collection.  The  pH  is  best  measured  in  a  morning  urine  specimen  after  an
overnight fast. If the pH of urine is higher than 7.6, urea splitting organisms must be
present, for the kidneys cannot produce urine in this range of alkalinity. Such a finding
strongly suggests that the stones are composed of magnesium ammonium phosphate.
Fixation of the pH at 6 to 6.5 is compatible with renal tubular acidosis. Consistently
low pH is a common cause of the formation of uric acid calculi.
B. Blood investigations
 Complete blood count: The white blood count may be increased as a result of
complicating  infection.  If  renal  function  is  not  adequate,  anaemia  may be
found.
 Renal function tests:  Blood urea nitrogen and serum creatinine will give an
indication of the functional status of the kidney.
 Serum blood chemistry: This investigation is usually done in recurrent stone
formers.  Fasting serum calcium and phosphates  should be determined on 3
occasions. Serum proteins should also be estimated, since almost half of the
calcium is normally unionized and bound to proteins. Hypercalcaemia is most
commonly  seen  in  association  with  osteolytic  or  disseminated  malignant
disease, especially cancers of the breast and lung, multiply myeloma, leukemia
and  sarcoidosis,  but  serum  phosphate  is  usually  normal.  Serum  alkaline
phosphatase  is  increased  in  hyperparathyroidism  only  if  bone  disease  is
present. Elevated serum uric acid is found in 50% of uric acid stone formers.
C. Plain X-ray: A plain film of the abdomen may show a calcific body in the region
of the kidney or in the ureter. This constitutes merely presumptive grounds for the
diagnosis.  Ureteric  calculi  often  looks  like  root  of  a  tooth,  sometime  it  may  be
confused with pelvic phleboliths which are usually round. 
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D. Excretory urography: Excretory urograms are useful in the diagnosis of ureteric
calculus. The ureterogram places the calcification in the ureter and also demonstrates
dilatation. 
E.  Ultrasonography: Ultrasonography is  a  noninvasive  method  of  demonstrating
both ureteral  calculi  and the  consequent  hydronephrosis.  Color  dropper  ultrasound
examination may demonstrate the increased resistive index in the obstructed kidney
and assymetry or absence of ureteral jets in urinary bladder.ons of the ureter above the
stone.
F. MRI: The study has potential usefulness when patients have renal impairment or
allergy to intravenous contrast agents and when X-rays are contraindicated. In contrast
to  CT,  not  only MRI is  unable  to  visualize  most  stones  but  invitro  studies  have
determined  that  this  modality  is  not  useful  for  characterizing  the  composition  of
stones.
G. Radioisotope methods: Radioisotope renography and scanning have contributed
to  the  diagnosis  of  obstruction  and  location  of  calculus  in  a  number  of  patients,
particularly those who are otherwise sensitive to contrast  media.  This technique is
helpful not only to the patients sensitive to the intravenous contrast and knowing the
location of the calculus but also the degree of urinary obstruction is clearly defined.
H. Instrumental examination: Cystoscope and ureteroscope is seldom needed for the
diagnosis of ureteral calculus.
I. Analysis of stone: Chemical analysis of renal calculi has been all but abandoned.
Significant  error  may  occur  because  qualitative  and  semiquantitative  chemical
methods  are  not  accurate.  Studies  have  shown  that  X-ray  diffraction;  Infrared
spectroscopy procedures are accurate in detecting components of urinary calculi9.
1.7 How are kidney stones treated?
Fortunately, surgery is not usually necessary. Most kidney stones can pass through the
urinary system with plenty of water (2 to 3 quarts a day) to help move the stone along.
Often,  patient  can  stay home during  this  process,  drinking fluids  and  taking pain
medication as needed. 
1.7.1 The first step: Prevention 
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If  a  patient  has had more than one kidney stone,  he is  likely to  form another;  so
prevention is very important. To prevent stones from forming, doctor must determine
their cause and he or she will order laboratory tests, including urine and blood tests.
Doctor will also ask about patient’s medical history, occupation and eating habits. The
passed or removed stone has to be analyzed in the laboratory, because its composition
helps in planning treatment. 
1.7.2 Lifestyle changes 
A simple  and  most  important  lifestyle  change  to  prevent  stones  is  to  drink  more
liquids; water is the best. If patient tends to form stones, he or she should try to drink
enough liquids throughout the day to produce at least 2 quarts of urine in every 24 h
period. People who form calcium stones used to be told to avoid dairy products and
other foods with high calcium content. However, recent studies have shown that foods
high in calcium, including dairy foods, help prevent calcium stones. Taking calcium in
pill form, however, may increase the risk of developing stones. 
1.7.3 Medical therapy 
 A 24-hour urine collection with measurement of the important  analytes is usually
reserved for use in patients with recurrent stone formation. In these patients, the major
urinary  risk  factors  include  hypercalciuria,  hyperoxaluria,  hypocitraturia  and
hyperuricosuria.  Effective  preventive  and  treatment  measures  include  thiazides
therapy to lower the urinary calcium level,  citrate supplementation to increase the
urinary citrate level and, sometimes, allopurinol therapy to lower uric acid excretion.
Uric acid stones are most often treated with citrate supplementation.   
1.7.3 Surgical treatment
Surgery should be reserved as an option for cases where other approaches have failed
or should not be tried. Surgery may be needed to remove a kidney stone, if it 
 Does not pass after a reasonable period of time and causes constant pain 
 Is too large to pass on its own or is caught in a difficult place 
 Blocks the flow of urine 
 Causes ongoing urinary tract infection 
 Damages kidney tissue or causes constant bleeding       
                                              Stone episode (resolved)
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                                                    Previous episode?
 
                                  No                                                                 Yes
Conservative management:                          Obtain history: Number of previous
episodes, Increase urine output to 2.1qt per day.         onset of previous episodes,
bowel disease,
Cosider lower sodium intake.                       gout, diabetes, medications, family history
Consider lower meat intake.
                                                                                            Serum studies
                                                                                            24-hour urine studies
Uncomplicated calcium stone disease                                            Other stone disease
(i.e., normocalcemia, no bowel
disease, no urinary tract infection)
Normo calciuria                Hypercalciuria
Prescride potassium         Treat with
Citrate.                              thiazide diuretics.
Add potassium chloride       Add potassium citrate
if patient has normal             if patient has low
urine citrate levels.               urine citrate levels.
Cystinuria         Uric acid calculi        Hypercalcemia       Hyperuricemia    Struvite
calculi
Prescribe              Prescribe                  Hyperparathyroid
Prescribe  tiopronin            potassium               investigation                 Prescribe
antibiotics.
(Thiola) and        citrate.                                                          allopurinol. 
increase fluid
intake.
                     Treat relapses                Treat based                         Add acetohydroxamic
                     With allopurinol                 on findings.                         acid (Lithostat) for
                     (Zyloprim).                                                          Severe infection stines.
                
     Fig 3: Algorithm for the medical management of recurrent urinary calculi
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 Until recently, surgery to remove a stone was very painful and required a recovery
time of 4 to 6 weeks. Today, treatment for these stones is greatly improved and many
options do not require major surgery. 
A. Extracorporeal shockwave lithotripsy 
Extracorporeal shockwave lithotripsy (ESWL) is the most frequently used procedure
for the treatment of kidney stones. In ESWL, shock waves that are created outside the
body travel through the skin and body tissues until they hit the denser stones. 
The stones  break  down into sand-like  particles  and  are  easily passed  through the
urinary tract in the urine10-11. 
1.8 Natural products used in the treatments of urolithiasis.
Ammannia baccifera12, Blackcurrant (Ribes nigrum)13,  Coleus aromaticus  14,  Costus
spiralis  Roscoe15, Cranberry (Vaccinium macrocarpon)16,  Cyclea peltata17,  Herniaria
hirsute18-19,  Lupeol  and  Betulin20-21,  Moringa  oleifera22,  Musa  paradisiaca23-24,
Phyllanthus  niruri25-26,  Raphanus  sativus27,  Salix  taxifolia28,  Tribulus  terrestris29-31,
Varuna  (Crataeva  nurvala)32-33,  Crataeva  adansonii34, Aerva  lanata35-36,  Bergenia
ligulata  rhizome37, Nigella  Sativa38, Eleusine  Coracana39, Hibiscus  sabdariffa40,
Quercus  salicina  Blume/Quercus  stenophylla  Makino41, Ammi  visnaga42,  Cynodon
dactylon43,  Orthosiphon  stamineus44,  Rotula  aquatica,  Commiphora  wightii  and
Boerhaavia diffusa45, Herniaria hirsuta and Agropyron repens46Tephrosia purpurea47.
1.9 Ethylene glycol induced urolithiasis:
Ethylene glycol is present in many common substances such as antifreeze, de-icing
substances,  detergents,  lacquers,  and  polishes.  Ethylene  glycol  itself  is  not  toxic;
rather the metabolites, glycolic acid and oxalic acid exert their toxic effects. Three
stages of toxicity from ethylene glycol are classically identified: 1) CNS stage, 30 min
to 12 hours after ingestion with features of altered mental status, ataxia and slurred
speech;  2)  cardiopulmonary  stage,  12-24  hours  after  ingestion  with  hypertension,
tachycardia, congestive heart failure, and  adult respiratory distress syndrome; 3) renal
stage, 24-72 hours after  ingestion with flank pain, calcium-oxalate crystalluria, and
oliguria48 Of interesting note, two forms of oxalate crystals can be present in the urine
in ethylene glycol poisoning, one more specific than the other. A dumbbell shaped
monohydrate crystal is most common, however the dihydrate form is most specific, as
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the  monohydrate  form  can  be  present  in  those  who  consume  large  quantities  of
vitamin C as well as diets high in urate. The dihydrate form also requires a higher
concentration of oxalate to be present, and is thus more indicative of ethylene glycol
poisoning49. 
Toxicity results from the depressant effects of ethylene glycol on the central nervous
system (CNS).Metabolic acidosis and renal failure are caused by the conversion of
ethylene glycol to noxious metabolites. Oxidative reactions convert ethylene glycol to
glycoaldehyde,  and  then  to  glycolic  acid,  which  is  the  major  cause  of  metabolic
acidosis.50-51 Both of these steps promote the production of lactate from pyruvate.52
The conversion of glycolic acid to glyoxylic acid proceeds slowly, further increasing
the serum concentration of glycolic acid.4 Glyoxylic acid is eventually converted to
oxalic acid and glycine. Oxalic acid does not contribute to the metabolic acidosis, but
it is deposited as calcium oxalate crystals in many tissues. Ethylene glycol is rapidly
absorbed by the stomach and small intestine, and is quickly redistributed throughout
the body.  Metabolites of ethylene glycol  remain in the body for  several  days,with
calcium oxalate present in tissues for much longer. The clinical syndrome of ethylene
glycol  intoxication  has  traditionally  been  divided  into  three  stages:  progressive
involvement of the CNS, the cardiopulmonary systems, and the kidneys. However,
presentation is highly variable and dependent on the amount ingested, the combined
ingestion with ethanol, and the timing of medical intervention.53
1.9.1 Clinical Manifestations
Ethylene glycol produces CNS depression similar to that of ethanol.  Symptoms of
ethyl-ene glycol toxicity include confusion, ataxia, hallucinations, slurred speech, and
coma.  Symptoms are most severe six  to 12 hours  after ingestion, when the acidic
metabolites of ethylene glycol are at  their maximal concentration The presentation
may be similar to ethanol intoxication, if the patient presents early or has consumed
small amounts of ethylene glycol. However, an ethanol odor will be absent, and serum
or  respiratory  ethanol  levels  will  be  too  low  to  account  for  the  degree  of  CNS
depression.  The  absence  of  a  strong  odor  of  alcohol  in  a  patient  who  appears
intoxicated should raise the suspicion of ethylene glycol ingestion. Following a period
of  CNS  depression,  metabolic  acidosis  and  cardiopulmonary  symptoms  become
prominent, although co ingestion of ethanol will delay the metabolic acidosis.  The
patient  may experience nausea,  vomiting,  hyperventilation,  and hypocalcemia with
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muscle tetany and seizures. Hypertension, tachycardia, and cardiac failure may ensue.
Pneumonitis,  pulmonary edema,  and  adult  respiratory distress  syndrome have also
been reported.54 Renal involvement may become apparent within 24 to 72 hours after
ingestion. Urinary crystal formation requires a sufficient amount of time for ethylene
glycol  to  be  metabolized  into  oxalate.  Calcium oxalate  formation  depletes  serum
calcium levels and deposits in intestinal mucosa, liver, brain, heart, lung, and kidney.
The excretion  of  calcium oxalate  crystals  in  the  urine  is  usually,  but  not  always,
present.  Oliguric or anuric renal failure is  the result in the most severe cases and,
although permanent renal failure is rare, recovery of renal function may take up to two
months. If untreated, severe ethylene glycol toxicity is usually fatal within 24 to 36
hours.55
1.9.2 Treatment
Current practice guidelines for initiating treatment of ethylene glycol poisoning have
been published by the American Academy of Clinical Toxicology (AACT) and are
listed in table.
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 Ethylene glycol is rapidly absorbed from the stomach, making treatment with gastric
lavage and syrup of ipecac ineffective. Likewise, it requires large amounts of activated
charcoal  to  bind  relatively small  amounts  of  ethylene  glycol,  and  the  therapeutic
window for this action is less than an hour. Traditional treatment of ethylene glycol
poisoning consists of sodium bicarbonate, ethanol, and hemo dialysis. Fomepizole is a
new agent with a specific indication by the U.S. Food and Drug Administration for the
treatment of ethylene glycol poisoning.56 Ethanol and fomepizole are thought to act as
inhibitors  of  alcohol  dehydrogenase  and  therefore  prevent  the  formation  of  acidic
ethylene  glycol  metabolites,  but  only fomepizole  has  demonstrated  this  ability.  If
patients are diagnosed and treated with these products early in the course of poisoning,
hemo dialysis may be avoided. Once severe acidosis and renal failure have occurred,
however,  hemodialysis  is  necessary.  Fomepizole  treatment  should  be  initiated
immediately  when  ethylene  glycol  poisoning  is  suspected.  Within  three  hours  of
initiating therapy with fomepizole, inhibition of metabolite production and resolution
of acidosis occurs, and the anion gap is normalized within four hours. If fomepizole
therapy is begun before a rise in the serum creatinine concentration, damage to the
kidney can be avoided. When compared with ethanol, the advantages of fomepizole
include  a  slower  rate  of  excretion  by  the  kidneys,  lack  of  CNS  depression  or
hypoglycemia, and easier maintenance of effective plasma levels. 
Ethanol may be administered orally or intravenously. The recommended therapeutic
blood ethanol level  is  100 to 150 mg per  dL (22 to  33 mmol per L).  The AACT
provides specific dosage recommendations for ethanol in patients receiving standard
treatment  and  patients  on  hemodialysis.  While  oral  ethanol  can  be  simply
administered, it  requires a conscious patient who is willing to drink the ethanol or
tolerate  the  placement  of  a  nasogastric  tube.  Advantages  of  intravenous  infusion
include greater absorption and no gastrointestinal upset. Disadvantages of treatment
with ethanol include variable metabolism of ethanol; inebriation and CNS depression;
frequent  monitoring  of  serum  concentrations  (every  one  to  two  hours);  difficulty
maintaining effective serum concentrations; and the need to administer ethanol in an
intensive care unit. Administration of intravenous sodium bicarbonate will correct the
metabolic  acidosis,  increase  the  elimination  of  renal  glycolic  acid,  and inhibit  the
precipitation  of  calcium oxalate  crystals,  although  the  latter  benefit  has  not  been
proved  in  clinical  trials.  Fifty  to  100  mEq  per  L of  intravenous  fluid  is  usually
sufficient, with a goal of maintaining a urine pH greater than 7.0.3 If the diagnosis of
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ethylene  glycol  poisoning  is  not  made,  and  the  acidosis  is  treated  only  with
bicarbonate,  organic acids  will  continue to be produced.10 Treatment with sodium
bicarbonate  may worsen  hypocalcemia  initially  because  of  the  protein  binding  of
calcium. Hemodialysis is effective in removing ethylene glycol and glycolic acid, and
correcting the metabolic acidosis.57 A serum ethylene glycol concentration greater than
50  mg  per  dL (8  mmol  per  L)  by  itself  is  no  longer  considered  a  criterion  for
hemodialysis. In the absence of renal dysfunction and significant metabolic acidosis,
the use of fomepizole should eliminate the need for hemodialysis in patients with high
serum ethylene glycol concentrations; in these patients, frequent monitoring of acid-
base  balance  is  necessary.  When  ethanol  or  fomepizole  is  administered  and  renal
failure  is  present,  dialysis  is  the  only  method  for  removal  of  ethylene  glycol.  If
metabolic  acidosis  persists,  too little  ethanol  or  fomepizole  is  being administered.
Traditionally, hemodialysis is continued until ethylene glycol and glycolic acid levels
cannot be detected in the blood, and there are no acid base disturbances. Prolonged
dialysis may not be necessary in patients treated with fomepizole or ethanol; the end
point for dialysis in these patients is correction of the anion and osmolar gaps. Serum
osmolality levels and electrolyte levels should be monitored closely every two to four
hours  for  12  to  24  hours  following  the  discontinuation  of  dialysis  because
redistribution  of  ethylene  glycol  may  result  in  an  elevated  serum  concentration.
Pyridoxine (vitamin B6) and thiamine (vitamin B1) in dosages of 100 mg daily are
believed  to  promote  the  conversion  of  intermediate  byproducts  into  nontoxic
metabolites, but clinical data supporting their effectiveness do not exist. Therapy with
100  mg  of  intravenous  thiamine  would  be  appropriate  if  ethanol  withdrawal  is
suspected. Parenteral calcium, given as gluconate or chloride salts, may be necessary
for treatment of tetany and seizures caused by hypocalcemia. 58 
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                           2. REVIEW OF LITERATURE 
                Lin SY et al reported Antioxidant, anti-semicarbazide-sensitive amine
oxidase,  and  anti-hypertensive  activities  of  geraniin  isolated  from  Phyllanthus
urinaria, Geraniin  also  showed  dose-dependent  inhibitory  activities  against
semicarbazide-sensitive amine oxidase (SSAO, IC50 were 6.58 microM) and against
angiotensin converting enzyme (ACE, IC50 were 13.22microM). For kinetic property
determinations, geraniin showed competitive inhibitions against SSAO (the apparent
inhibition  constant,  Ki,  was  0.70microM)  and  mixed  noncompetitive  inhibitions
against ACE. The geraniin showed antihypertensive activity in lowering SBP and DBP
and showed a significant difference from the blank (distilled water) at 2, 4, 6, 8, and
24  h.  Healthy  food  products  could  use  geraniin  for  antioxidant  protection  and
therapeutic effects in the future.
                Lee et al reported Hepatoprotective effect of Phyllanthus in Taiwan on acute
liver  damage  induced  by  carbon  tetrachlorideThe  effect  of  oral  administration  of
Phyllanthus methanolic extracts (PME) (P. urinaria L.s.  urinaria is  hepatoprotective
and antioxidant agents.
                Chularojmontri  L  et.al reported Antioxidative and cardioprotective effects of
Phyllanthus urinaria L. on doxorubicin-induced cardiotoxicity. 
               Shen ZQ ,et al  investigated  the effects of PUW (a fraction containing 60%
corilagin  from  a  Chinese  herbal  plant  Phyllanthus urinaria)  on  thrombosis  and
coagulation system.They showed that PUW administered intravenously significantly
decreased the mouse mortality, prolonged the occlusion time of rat carotid arteries,
and reduced the wet and dry thrombus weight of the inferior vena cava, respectively.
PUW markedly inhibited the binding of activated platelets to neutrophils, obtaining
39.7 mg/L of the medium inhibitory concentration. Intravenously administered PUW
significantly shortened ELT, prolonged KPTT while had no influence on PT; PUW
increased BT in rat tail tips but the BT caused by PUW was much shorter than that by
aspirin or urokinase.
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                  Zhang LZ et al reported     Isolation and identification of a novel
ellagitannin from  Phyllanthus urinaria L. Phyllanthusiin G is a new compound was
isolated. A novel ellagitannin named phyllanthusiin G was isolated, its structure was
established as 1-O-galloyl-2-phyllanthoyl-3,6-(R)-HHDP-beta-D-glucose.
               Xu M, et al reported Phenolic antioxidants from the whole plant of
Phyllanthus urinaria The 1,1-diphenyl-2-picrydydrazyl (DPPH) assay on the extract of
Phyllanthus urinaria L.  (Euphorbiaceae)  displayed  considerable  radical-scavenging
activity (SC50 = 14.3 microg/ml). Further bioassay-guided purification of the extract
led to the isolation of a series of 15 phenolic compounds, including the ellagitannins
1-7, the flavonoids 8-10, and the simple hydroxylated (or glycosylated) aromatic acids
11-15. Their structures were identified by spectroscopic analyses and comparison with
authentic samples or literature data. The structure of repandinin B (1) was for the first
time fully assigned by 1D- and 2D-NMR experiments. The phenolic compounds 1, 3,
4, 6, 9, 11, and 15 have not been isolated before from the title plant. 
                 Zhong Y et al reported Chemical constituents of Phyllanthus urinaria L. and
its antiviral activity against hepatitis B virus. Studies on the chemical constituents of
Phyllanthus urinaria and its antiviral activity against hepatitis B virus were completed.
Eleven compounds have been isolated. Two of them are new compounds methyl ester
dehydrochebulic  acid  and  methyl  brevifolin  carboxylate.  Antiviral experiments  on
HBsAg in  vitro  and  liver  damage  caused  by  CCl4  have  shown  that.  Phyllanthus
urinaria possesses antiviral activities against HBV.
               Paulino N, et al reported The relaxant effect of extract of  Phyllanthus
urinaria in the guinea-pig isolated trachea. Evidence for involvement of ATP-sensitive
potassium channels. indicate that the ATP-activated potassium channels sensitive to
glibenclamide, but not the small conductance calcium-activated potassium channels
sensitive to apamin, largely contribute to the relaxation effect of the hydroalcoholic
extract of P.  urinaria in GPT. In addition, both beta 2 and VIP-mediated responses
seem to account, at least in part, for the relaxation effect of the hydroalcoholic extract,
as its relaxant response was partially attenuated by both propranolol and VIP receptor
antagonist.
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3.1 Aims: 
Urolithiasis is defined as the presence of one or more calculi in any location within the
urinary tract. Urolithiasis is the third most common disorder of the urinary tract, the
others  being  frequently  occurring  urinary  tract  infections  and  benign  prostatic
hyperplasia.  The worldwide  incidence  of  urolithiasis  is  quite  high  and in  spite  of
tremendous advances in the field of medicine, there is no truly satisfactory drug for
the treatment of renal calculi. Most patients still have to undergo surgery to be rid of
this  painful  disease.  Hyperoxaluria  is  the  main  initiating  factor  for  urolithiasis.
Phyllanthus urinaria is said to be useful  in the treating urinary calculi. Hence the
present study an effort has been made to establish the scientific validity for the anti-
urolithiatic activity.
3.2 OBJECTIVES OF THE STUDY:
1. To prepare ethanolic extract of Phyllanthus urinaria
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2. To  study  the  phytochemical  screening  of  ethanolic  extract  Phyllanthus
urinaria
3. To study the acute oral toxicity ethanolic extraction of Phyllanthus urinaria
4. To  study  the  antiurolithiatic  activity  of  ethanolic  extract  of  Phyllanthus
urinaria in rats
5. To carry out histopathological studies.
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4. PLANT PROFILE 
4.1  Plant profile of Phyllanthus urinaria: 
Phyllanthus urinaria is an annual plant with the main stem erect, un  branched or
sparsely branched and seldom more than a foot tall. The side branches with their two
rows of alternate leave resemble a compound leaf. The leaves themselves are finely
hairy, nearly sessile (stalkless), oblong to narrowly obovate.
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                                              Phyllanthus urinaria
Rank Scientific Name and Common Name
Kingdom Plantae 
Subkingdom Tracheobionta 
Superdivision Spermatophyta 
Division Magnoliophyta 
Class Magnoliopsida 
Subclass Rosidae 
Order Euphorbiales 
Family Euphorbiaceae 
Genus Phyllanthus  L. 
Species Phyllanthus urinaria  L. 
     
Meniran  has  proven  to  be  antihepatotoxic,  antiviral,  antibacterial  and
hypoglycemic; also used for the elimination of kidney- and gallstones. It is excellent
in treating liver- and kidney ailments; used extensively for detoxification
       Phyllanthus urinaria (P. urinaria), one of the herbal plants belonging to the genus
Phyllanthus  (Euphorbiaceae),  is  widely  distributed  in  China,  Southern  India  and
Southern America. It has long been used in folk medicine for the treatment of several
diseases such as hepatitis  B, neprolithiasis and in painful  disorders59-61  7’-hydroxy-
3’,4’,5,9,9’-pentamethoxy-3,4- methylene dioxy lignan isolated from the ethyl acetate
extract of P. urinaria was shown to exhibit anticancer activity by inducing apoptosis
through the inhibition of telomerase activity and Bcl-2 expres- sion.62 previous studies
also demonstrated that the water extract prepared from  P. urinaria has an anti- cancer
effect  on Lewis lung carcinoma cells  through a similar  pathway.63 In  addition,  we
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4.4Overview;
Shatterstone is a small tropical annual herb growing up to 2 feet tall. Along the erect, red
stem are equally set small green, oblong feathered leaves. It has greenish white flowers. A
very small  wart-like fruit,  greenish-red,  is  underneath every pair of the feathered leaves.
When the plant is picked the feathery leaves fold in, completely closing themselves. The
plant is used for several conditions such as blennorrhagia (gonorrhea), diabetes, dysentery,
flu, tumors, jaundice (the yellow color of the skin and whites of the eyes caused by excess
bilirubin  in  the  blood),  vaginitis  (swelling,  itching,  burning  or  infection  in  the  vagina),
against headache, fever, conjuntivitis (pinkeye or bloodshot eyes), menstrual disorders and
dyspepsia (pain or an uncomfortable feeling in the upper middle part of the stomach). 
4.5         Pharmacology
The  primary  action  of  shatterstone  is  on  the  liver;  it  acts  by the  inhibition  of  DNA
polymerase on the hepatitis B virus. The enzyme DNA polymerase is needed for the virus
to  reproduce.Several  studies  suggest  that  Phyllanthus  urinaria  works  better  than  the
related species p. amarus, p. debilis and p.niruri in the treatment of hepatitis B. An equally
important action is the use against kidney stones (renal calculi), urinary tract- and bladder
infections. In preliminary research in animals, extracts of Phyllanthus plants have shown
promising  results  in  pain  relief.  The  mechanism seems to  be  that  this  is  reached  by
decreasing inflammation. 
     
demonstrated that the anti-tumor and anti-angiogenic effects of  P. urinaria in mice
bearing Lewis lung carcinoma were due to interference with migration of vascular
endothelial cells but not viability.64 Therefore, P. urinaria became our study target and
we prepared the drug with a standardized protocol under regulation and used it for
further investigation. 
Department of pharmacology Page 27
     
                                 5. MATERIALS AND METHODS   
 Materials and methods                                
 Materials- 
Plant  material  -  Plant  material:  The  plant  of  Phyllanthus  urinaria plants  were
collected  from  the  certified  ayurvedic  wholesaler.  The  plant  was  identified  and
authenticated by Asst. Prof. Dr. K. Madhava chatty, MSc, Med, Department of Botany,
S.V. University, Tirupati
Drugs and Chemicals
Cystone  (Himalaya  Pharmaceutical,  Banglore),  Ethylene  glycol  (SRL  Mumbai),
Tween  80  (Merck  Pvt  Ltd,  B,  Mumbai),  Anaesthetic  ether  (SD  Finechem  Ltd.,
Mumbai), Chloroform (SD Finechem Ltd .Mumbai). Formaline (SD Finechem Ltd.,
Mumbai) and all other chemicals and reagents were of analytical grade.
Diagnostic kits:  
Diagnostic  kits  used  for  estimation  of  Creatinine,  Urea,  Uric  acid,  Calcium,
Phosphorus,  Calcium oxalate were procured from  Robonik Diagnostic Ltd India.
Instruments: 
Autoanalyzer  (Robonik),  Refrigerator  centrifuge  (MPW-350R),UV-Spectro-phot
ometer  (UV-1601,  Shimadzu  Corporation,  Kyoto,  Japan),  Mini  Lyotrap  (LTE
Scientific  Ltd.),  Research  centrifuge  (Remi  industries,  Mumbai)  and  homogenizer
(Remi Motors, Mumbai). Dhona balance (M/S Dhona instruments Pvt. Ltd., Kolkata,
India).
Experimental Animals:
Wistar albino male (180–220 g) was obtained from the central animal house of Sigma
Institute  of  Clinical  Research  and  administration Pvt  Ltd Hyderabad.  The animals
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were housed at room temperature (22-28 ºC) for 12 hr dark and 12 hr light cycle and
given standard laboratory feed and water  ad-libitum.  The study was approved and
conducted  as  per  the  norms  of  the  Institutional  Animal  Ethics  Committee
(180/SICRA/IAEC).
Acute toxicity study
Procedure: Acute toxicity studies were performed according to OECD-423guidelines
category IV substance (acute toxic class method). Swiss albino mice (n=3) of either
sex selected by random sampling technique were employed in this study. The animals
were fasted for 4 hrs with free access to water only. The plant extracts of Phyllanthus
urinaria were administered orally with maximum dose of 2000 mg/kg body weight.
The mortality was observed for three days. If mortality was observed in 2/3 or 3/3 of
animals, then the dose administered was considered as a toxic dose. However, if the
mortality was observed only one mouse out of three animals then the same dose was
repeated again to confirm the toxic effect. If mortality was not observed, the procedure
was  then  repeated  with  higher  dose  (Organization for  economic  Co-operation  and
development, 2001).68
Observations  
Animals  were  observed  individually  at  least  once  during  the  first  30  minutes
after dosing, periodically during the first 24 hours (with special attention given during
the first 4 hours) and daily thereafter, for a total of 14 days. All observations were
systematically recorded  with individual  records  being maintained  for  each  animal.
Observations  included  changes  in  skin,  mortality  and  general  behavioral  pattern.
Attention was given  for  observations  of  tremors,  convulsions,  salivation,  diarrhea,
lethargy, sleep and coma. No death was observed till the end of study.
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Acute Toxicity Record Sheet of Phyllanthus urinaria
Title: Evaluation of LD50   Phyllanthus urinaria
Drug: Phyllanthus urinaria                                              Dose: 2000 mg/kg BW                   Species: Albino mice Sex: Male & Female
     Date:                                                                                                                                                                     Duration: 24 hours
S.no
.
Code Toxicity Time
 
Of  Death
Observation
Onset Stop Skin 
colour
Eyes Res
p
CNS Tre Con Sali Dia
h
Slee
p
Leth Co
m
1. EPU x x X x x x x X X x x x x X
(*TRE-Tremor, CON-Convulsions, SALI- Salivation, Diah - Diarrhea, LET-Lethargy)                      x = Negative,  = Positive
EPU: Ethanolic extract of Phyllanthus urinaria
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Qualitative chemical test:69
Preliminary  phytochemical  studies:  Ethanolic  extract  of  the  plant  of  Phyllanthus
urinaria were subjected to chemical tests for the identification of their active constituents.
1. Tests for carbohydrates and glycosides
A small quantity of the extract was dissolved separately in 4 ml of distilled water and
filtered.   The  filtrate  was  subjected  to  Molisch’s  test  to  detect  the  presence  of
carbohydrates.
A. Molisch’s Test
Filtrate was treated with 2-3 drops of 1% alcoholic α-naphthol solution and 2ml of con.
H2SO4 was added along the sides of the test tube. Appearance of violet coloured ring at
the junction of two liquids shows the presence of carbohydrates. Another portion of the
extract was hydrolysed with HCl for few hours on a water bath and the hydrolysate was
subjected to Legal’s and Borntrager’s test to detect the presence of different glycosides.
B. Legal’s Test
To the hydrolysate, 1ml of pyridine and few drops of sodium nitroprusside solution were
added and then it was made alkaline with sodium hydroxide solution. Appearance of pink
to red colour shows the presence of glycosides.
C. Borntrager’s Test : Hydrolysate was treated with chloroform and then the chloroform
layer  was  separated.   To  this  equal  quantity  of  dilute  ammonia  solution  was  added.
Ammoniacal layer acquires pink colour showing the presence of glycosides.
2. Tests for alkaloids: A small portion of the methanol extract was stirred separately with
few drops of  dil.  HCl and filtered.   The filtrate  was treated with various reagents as
shown for the presence of alkaloids.
Mayer’s reagent         -   Creamy precipitate 
Dragandroff’s reagent       -   Orange brown precipitate 
Hager’s reagent          -    Yellow precipitate 
Wagner’s reagent          -     Reddish brown precipitate
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3. Tests for phytosterol
The extract was refluxed with solution of alcoholic potassium hydroxide till complete
saponification takes place. The mixture was diluted and extracted with ether. The ether
layer was evaporated and the residue was tested for the presence of phytosterol.
Libermann Burchard Test
The residue was dissolved in few drops of acetic acid, 3 drops of acetic anhydride was
added followed by few drops of con. H2SO4.  Appearance of bluish green colour shows
the presence of phytosterol.
4. Tests for fixed oils
Spot test
Small quantity of extract was separately pressed between two filter papers. Appearance of
oil stain on the paper indicates the presence of fixed oil. Few drops of 0.5N alcoholic
potassium hydroxide were added to a  small  quantity of  extract  along with a  drop of
phenolphthalein.  The mixture was heated on water bath for 1-2 hours. Formation of soap
or partial neutralization of alkali indicates the presence of fixed oils and fats.
5. Tests for gums and mucilages
Small quantity of the extract  was added separately to 25 ml of absolute alcohol with
constant  stirring  and  filtered.  The  precipitate  was  dried  in  air  and  examined  for  its
swelling properties for the presence of gums and mucilages.
6. Tests for Saponins
The extract was diluted with 20 ml of distilled water and it was agitated in a graduated
cylinder for 15 minutes.  The formation of 1cm layer of foam shows the presence of
saponins.
7.Tests for proteins and free amino acids
Small quantity of the extract was dissolved in few ml of water and treated with following
reagents.
A. Millon’s reage Appearance of red colour shows the presence of protein   and free
amino acids.
B.  Ninhydrin reagent - Appearance of purple color shows the presence of   proteins and
free amino acids.
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C.  Biuret test - Equal volumes of 5% NaOH solution and 1% copper sulphate solution
were added. Appearance of pink or purple colour shows the presence of proteins and free
amino acids.
8.Tests for phenolic compounds and tannins
Small quantity of the extract was taken separately in water and tested for the presence of
phenolic compounds and tannins using following reagents.
A. Dil.FeCl3 solution (5%)                                                   -violet colour
B. 1% solution of gelatin containing 10% NaCl               - white precipitate
C. 10% lead acetate solution                                                   - white precipitate.
9. Tests for flavonoids
A. With aqueous Sodium hydroxide solution:
Blue  to  violet  colour  (anthocyanins),  yellow  colour  (flavones),  yellow  to  orange
(flavonones)
B. With Con. H2SO4:
Yellow  orange  colour  (anthocyanins),  yellow  toorange  colour  (flavones),  orange  to
crimson (flavonones)
C. Shinoda’s test
Small quantity of the extract was dissolved in alcohol and to that a piece of magnesium
followed by Con. HCl drop wise was added and heated.  Appearance of magenta colour
shows the presence of flavonoids.
The results of preliminary phytochemical studies of the plant extract are presented.
PHARMACOLOGICAL SCREENING MODEL
Ethylene glycol & ammonium chloride induced urolithiasis model12
Thirty  healthy adult  Wistar  albino  strain  rats  of either  sex  weighing  180-220g were
randomly divided into five groups. Each group consisted of 6 animals. The treatment
period was considered for 10 days.
Group 1: Normal rats were fed with standard rat chow diet and tap water ad libitum for
10 days. 
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Group 2: EG and ammonium chloride intoxicated rats were given normal lab diet  +
drinking water containing 0.75% [v/v] ethylene glycol (EG) and 2% [w/v] ammonium
chloride (AC) for 10 days to induce urolithiasis. 
Group 3: Standard group were fed with normal lab diet  + drinking water containing
0.75% [v/v] EG and 2% [w/v] AC + Cystone (5 ml/kg) for 10 days. 
Group 4: the test groups treated with ethanolic extract  Phyllanthus urinaria 200 mg/kg
with normal lab diet + drinking water containing 0.75% [v/v] EG and AC 2% [w/v].
Group 5:  the test groups treated with ethanolic extract Phyllanthus urinaria 400 mg/kg
of body weight were fed with normal lab diet + drinking water containing 0.75% [v/v]
EG and AC 2% [w/v].
URINE AND BLOOD SAMPLING
The  crystalluria  and  stone  formation  was  verified  by different  biochemical  marker
analysis of urine and serum. The urine samples of the test animals in different groups
were collected in their respective end day of the experiment (1%) EG model on 10th day
in (0.75%) EG + (2%) AC model.  The collected urine sample volume and PH were
measured followed by centrifugation at 3000 rpm for 10 minutes. After centrifugation
Department of pharmacology Page 35
the  urine  samples  were  examined  under  light  microscope  (LAICA,  DME Germany
400X) to ensure the presence of oxalate microcrystal followed by biochemical analysis
(urine oxalate, calcium and uric acid, creatinine, urea, magnesium and phosphorus). The
blood  samples  were  collected  from  the  animals  under  anaesthesia  (ether)  before
sacrificing. The collected blood samples were then centrifuged to obtain serum for the
analysis of serum creatinine and serum calcium, creatinine, urea, uric acid, magnesium
and phosphorus.
Estimation of serum and urine parameters:
SERUM CREATININE (Mod. Jaffe’s kinetic method)62
Principle 
Picric acid in alkaline medium reacts with creatinine to form a orange coloured complex
with the alkaline picrate. Intensity of colour formed during the fixed time measured at
520 nm is directly proportional to the amount of creatinine present in sample.
Creatinine + alkaline picrate                             Creatinine picrate complex
Pipette  in  to  test
tubes
Standard Sample
Working reagent 1000 µl 1000µl
Standard 100 µl ……..
Sample ……… 100 µl
Mix and read the variation of absorbance (∆A) between 30 seconds and 90 seconds
Calculation :
With standard or calibrator
Concentration in sample (mg/dl) =   Concentration of Standard   X  ∆ A 
Sample 
                                                                  ∆ A Standard
URIC ACID63
Principle:
Uric acid is oxidized to allantoin by uricase. The generated hydrogen peroxide reacts with
4-aminoantipyrine and DHPS to quinoneimine. 
                                         Uricase
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Uric acid + H2O + O2                         Allantoin + CO2 + H2O2
DHPS + 4-Aminoantipyrine + 2 H2O2                       Quinoneimine + 3 H2O
   Assay procedure
Pipette  in  to  test
tubes
Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 25µl ……… ……..
Standard ……… 25 µl ……..
Sample ………. ……… 25 µl
Mix and read the absorbance (A) after a 10 minutes incubation but within 30 minutes.
Calculation : 
With standard or calibrator
                                       Concentration of Standard
Reagent Blank                         Abs. Standard - Abs. of Reagent Blank
UREA64
Principle
Enzymatic determination according to the following reactions : 
                          Urease
Urea + 2H O                         2NH4++ Co3-2 
                                               GLDH
 NH4+ +Tris Base + NADH                         L-Glu+NAD+ + H2O
ASSAY PROCEDURE: Two Reagent Procedure 
Standard Sample / Control
R1 800 µl 800 µl
R2 200 µl 200 µl
Mix and Incubate at 37°C for 2 minutes then add
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Pipette in to test tubes Standard Sample
Working reagent 1000 µl 1000µl
Standard 10µl ……..
Sample ……… 10µl
Mix and read the variation of absorbance (∆A) between 30 seconds and 60 seconds.
Calculation :
With standard or calibrator
                                                         Concentration of Standard
Concentration in Sample (mg/dl) =                                            X ∆ A Sample
                                                                ∆ A Standard
CALCIUM (OCPC)
 Principle :
Ortho-Cresolphthalein Complexone reacts with calcium ions in alkaline medium forming
a  red-violet  color.  Interference  by  magnesium  is  eliminated  by  addition  of  8-
hydroxyquinoline. The colour intensity is directly proportional to the serum total calcium
concentration.
Assay procedure:
Pipette  in  to  test
tubes
Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 10µl ……… ……..
Standard ……… 10µl ……..
Sample ………. ……… 10 µl
Mix and read the absorbance (A) after 5 minutes incubation, but within 30 minutes.
Calculation :
With standard or calibrator.
                                             Concentration of Standard
Conc. of unknown Sample =                                            X Abs. of unknown Sample –      
Abs. of Reagent Blank
                                   Abs. Standard – Abs. of Reagent Blank
PHOSPHORUS
Principle :
Ammonium molybdate + Sulfuric Acid                            Phosphomolybdate complex
Assay procedure :
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Pipette  in  to  test
tubes
Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 10µl ……… ……..
Standard ……… 10µl ……..
Sample ………. ……… 10 µl
Mix and read the absorbance (A) after a 5 minutes incubation.
Calculation :
With standard or calibrator.
                                             Concentration of Standard
Conc. of unknown Sample =                                            X Abs. of unknown Sample –      
Abs. of Reagent Blank
                                   Abs. Standard – Abs. of Reagent Blank
Oxalate
Principle:
Oxalate is co-precipitated with calcium sulphate, reduced to glycolic acid by boiling with
dilute sulphuric acid and a zinc pellet and estimated colorimetrically with chromotropic
acid.
Procedure:
Set the auto-analyzer instrument with the parameters given along with the kit. Prepare the
working,  standard and test  solutions  as  per  the protocol.  Incubate for  5  min at  room
temperature mix and read on colorimeter.
Calculations: 
Oxalate (mg/dl)= Absorbance of Test × Concemtration of Standard (mg/dl)
                             Absorbance of standard
MAGNESIUM
Principle:
Magnesium combines  with  calmagite  in  an  alkaline  medium to  form a  red  coloured
complex. Interference of calcium and proteins is eliminated by the addition of specific
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chelating agent and detergents, Intensity of the colour formed is directly proportional to
the amount of magnesium present in the sample.
Magnesium+Calmagite         Alkaline mdeium        Red coloured complex
Procedure: 
Set the auto-analyzer instrument with the parameters given along with the kit. Prepare the
working standard and test solutions as per the protocol. Incubate for 5 min at room temp.
Mix and read 510 nm within 30 min.
Calculations:
Magnesium mEq/L=  Absorbance of Test    × 2
                                 Absorbance of standard
HISTOPATHOLOGY
The abdomen was cut open to remove both kidneys from each animal. Isolated kidneys
were  rinsed  in  an  ice-cold  physiological  solution,  after  the  extraneous  tissues  were
removed. The right kidney was fixed in 10% neutral buffered formalin, processed in a
series of graded alcohol and xylene, embedded in paraffin wax, sectioned at 5 µm and
stained with hematoxylin and eosin (H and E) for histopathological  examination. The
slides were examined under a light microscope to study the architecture of the kidney and
calcium oxalate deposits. 
ENZYME ASSAY
A portion of  kidney was taken from all the groups,  and a 30% w/v homogenate was
prepared  in  0.9%  buffered  KCl  (pH  7.4)  for  the  estimation  of  protein,  superoxide
dismutase (SOD), catalase (CAT), glutathione (GSH) and malondialdehyde (MDA).
1. Lipid Peroxidation: 
Malondialdehye,  formed  from  the  breakdown  of  polyunsaturated  fatty  acids,
serves  as  a  convenient  index  for  determining  the  extent  of  peroxidation  reaction.
Malondialdehye reacts  with thiobarbituric  acid (TBA) to  produce red colored species
which is measured at 532 nm.
Reagents:
1. TBA-TCA-HCl reagent.
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15% w/v TCA, 0.375 %w/v TBA and 0.25 N HCl. This solution was mildly heated to
assist the dissolution of TBA
1 ml of kidney homogenate was combined with 2 ml of TCA-TBA-HCl reagent  and
mixed thoroughly.  The solution was heated for 15 min. in a boiling water bath. After
cooling, the flocculent precipitate was removed by centrifugation at 1000 rpm for 10 min.
the absorbance of the supernatant was measured at 532 nm against a blank that contains
all the reagents minus the kidney homogenate. The malondialdehyde concentration of the
sample can be calculated using an extinction coefficient of 1.56x105M-1cm-1
Malondialdehyde concentration (M) =      Absorbance 
        1.56 x 105
2. Estimation of SOD
The  activity  of  superoxide  dismutase  was  determined  by  the  method  of  Misra  and
Fridovich  (1972)  based  upon  the  ability  of  SOD  to  inhibit  the  auto-oxidation  of
epinephrine to adrenochrome at alkaline pH inhibition of the chromagen formation by
superoxide dismutase was linear with increase in enzyme concentration.
Reagents:
1. Sodium carbonate buffer 0.1M (pH 10.2)
2. Ephinephrine(1mM)
The entire supernatant 1 ml (S) was taken in 0.1 M carbonate buffer (pH 10.2). After
addition of epinephrine, the increase in absorbance was measured at 480 nm using a UV–
Visible double beam spectrophotometer. The activity of the enzyme has been expressed
as U/mg protein, where 1U of the enzyme is defined as the amount of enzyme required to
inhibit the rate of epinephrine auto-oxidation by 50% under the conditions of the assay.
3. Estimation of Catalase
In the presence of catalase, H2O2 shows a continual decrease in absorbane in UV
range. The decomposition of H2O2 can be followed directly by the decrease in absorbance
at 240nm (E240  = 0.00394 ±0.0002 ltr mmol-1 mm-1). The difference in absorbance (∆ A
240) per unit time is a measure of the catalase activity.
Reagents: 
1. PBS 50 mM; pH7.0
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Dissolve (a)6.81 of KH2PO4 and (b) in the proportion 1:1.5(v/v).
2. H2O2 (0.17 mM): dilute 0.16 ml of (30%w/v) H2O2 with Phosphate buffer to 100
ml.
The catalase activity was determined spectrophotometrically according to the protocol of
Claiborne (1985).The reaction mixture (2 ml) contained 1.95 ml 10 mM H2O2 in 60 mM
phosphate buffer (pH 7.0).The reaction was started by adding 0.05 ml supernatant and the
absorbance was followed for 3 min at 240 nm. Phosphate buffer (60 mM, pH 7.0) was
used as a reference. The extinction coefficient of 0.04 mM−1cm−1 was used to determine
the  specific  activity  of  catalase.  A unit  of  catalase  is  defined  as  the  quantity,  which
decomposes 1.0µmole of H2O2  per min at pH 7.0 at 250C, while this H2O2  concentration
falls from 10.3to 9.2mM.The data was expressed as U/mg protein
4. Estimation of glutathione (GSH):
Principle: GSH is a non protein compound containing sulphydryl group in its structure.
DTNB (5,5’ di thio bis (2-Nitrobenzoic acid) is a disulfide chromagen that is reduced by
sulphydryl compounds to an intensly yellow colored compound. The absorbance of the
reduced  chromagen  is  measured  at  412  nm and  is  directly  proportional  to  the  GSH
concentration.
Reagents:
1. 10% Trichloroacetic acid (TCA)
2. Phosphate buffer (0.2M) pH 8.0
0.218 g Sodium dihydrogen phosphate and 2.641 g disodium hydrogen
phosphate in 100 ml distilled water
3. DTNB (0.6 mM) (pH 8)
11.9 mg in 50 ml Phosphate buffer 
GSH was measured by the method of Moran et al(1979).The kidney homogenate
proteins were precipitated by 10% TCA, centrifuged and the supernatant was collected. 1
ml of supernatant was mixed with 6 ml of 0.2 M Phosphate buffer pH 8.0 and 1 ml 0.6
mM  DTNB and  incubated  for  10  min  at  room  temperature.  The  absorbance  of  the
samples  was  recorded  against  the  blank  at  412  nm and  the  GSH concentration  was
calculated  from  the  standard  curve  by  multiplying  with  the  dilution  factor
(mannervik1985; tetza 1969)
Statistical analysis
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Results were indicated in terms of mean ± SEM. Statistical significance of data were
assessed by analysis of variance (One way-ANOVA), followed by comparison between
different  groups  using  ‘Dunnett’s  multiple  comparison  test.  The  significance  was
considered at the level of P<0.05.
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                                                     6.RESULTS 
Preliminary phytochemical screening
The extract of drug were analysed for the presence of various constituents. The result of 
this preliminary phytochemical examination is shown in Table no. 
Table No. Qualitative chemical examination of ethanolic extract of Phyllanthus 
urinaria.
Phytoconstituents Presence or Absence
Carbohydrates +
Glycosides +
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Fixed oils and fats +
Gums & mucilage -
Potein & amino acids -
Saponins ++
Tannins +
Phytosterols +
Flavonoids +++
Alkaloids +++
PHARMACOLOGICAL ACTIVITY
Acute oral toxicity 
Acute oral toxicity was carried out according to OECD guideline. EPU was safe upto 
2000mg/kg.
Effect of ethanolic extract of Phyllanthus urinaria on urinary volume and pH against
EG and AC induced urolithiasis.
EG and AC (0.75 and 2%.) administration showed significant (p<0.001) alteration of the
output of urine and pH as compared normal group. Administration of Cystone 5ml/kg,
EPU 200 and 400 mg/kg caused significamtly increased (p<0.01, p<0.05) urine output
and pH of the urine as compared to control (EG and AC) group. 
Effect of ethanolic extract of Phyllanthus urinaria on serum biochemical parameters
against EG and AC induced urolithiasis.
Serum Creatinine
Administration of EG and AC (0.75% and 2%) for 10 days caused significant elevation
(p<0.01) in serum creatinine concentration compared to normal one.  Standrad cystone
5ml/kg causes significant reduction (p<0.001) in serum creatinine concentration when
compared to EG and AC alone treated group.  Pretreatment with EPU 200 and 400mg/kg
causes  significant  reduction  (p<0.05  and  p<0.001)  in  serum  creatinine  concentration
when compared to EG and AC alone treated group.
Serum Urea 
Administration of EG and AC (0.75% and 2%) for 10 days caused significant elevation
(p<0.001) in serum urea concentration compared to normal one. Standrad cystone 5ml/kg
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causes significant reduction (p<0.001) in serum urea concentration when compared to EG
and  AC  alone  treated  group.   Pretreatment  with  EPU  200  and  400mg/kg  causes
significant reduction (p<0.01 and p<0.01) in serum urea concentration when compared to
EG and AC alone treated group.
Serum Uric Acid
Administration of EG and AC (0.75% and 2%) for 10 days caused significant elevation
(p<0.01) in serum uric  acid concentration compared to normal one.  Standrad cystone
5ml/kg causes  significant  reduction (p<0.001) in  serum uric  acid concentration when
compared to EG and AC alone treated group.  Pretreatment with EPU 200 and 400mg/kg
causes significant reduction (p<0.05 and p<0.001) in serum uric acid concentration when
compared to EG and AC alone treated group.
Serum Calcium
Administration of EG and AC (0.75% and 2%) for 10 days caused significant elevation
(p<0.001) in serum calcium concentration compared to normal one.  Standrad cystone
5ml/kg  causes  significant  reduction  (p<0.001)  in  serum  calcium  concentration  when
compared to EG and AC alone treated group.  Pretreatment with EPU 200 and 400mg/kg
causes significant reduction (p<0.001 and p<0.001) in serum calcium concentration when
compared to EG and AC alone treated group.
Serum Oxalate
Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.001)  in  serum oxalate  concentration compared  to  normal  one.  Standrad  cystone
5ml/kg  causes  significant  reduction  (p<0.001)  in  serum  oxalate  concentration  when
compared to EG and AC alone treated group.  Pretreatment with EPU 200 and 400mg/kg
causes significant reduction (p<0.05 and p<0.001) in serum oxalate concentration when
compared to EG and AC alone treated group.
Serum Phosphorus
Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.001) in serum phosphorus concentration compared to normal one. Standrad cystone
5ml/kg causes significant reduction (p<0.001) in serum phosphorus concentration when
compared to EG and AC alone treated group.  Pretreatment with EPU 200 and 400mg/kg
causes  significant reduction (p<0.05 and p<0.001) in serum phosphorus concentration
when compared to EG and AC alone treated group.
Serum Magnesium
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Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.05) in serum magnesium concentration compared to normal one. Standrad cystone
5ml/kg causes significant reduction (p<0.01) in serum magnesium concentration when
compared to EG and AC alone treated group.  Pretreatment with EPU 200 and 400mg/kg
causes  significant reduction (p<0.01 and p<0.001) in serum magnesium concentration
when compared to EG and AC alone treated group.
Treatment group Urinary Volume
(ml/24hr)
Urine Ph
Normal 18.4±0.97 7.5±2.1
Control (EG+AC) 6.96±0.69a 4.5±1.39a
Standard Cystone (5ml/kg) 14.93±0.57*** 8.2±1.32**
EPU 200mg/kg 8.41±0.45* 5.9±1.21*
EPU 400mg/kg 9.9±0.64* 6.14±2.24**
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Treatment group
Serum Biochemical Parameters
Creatinine 
mg/dl
Urea
mg/dl
Uric Acid
mg/dl
Calcium
mg/dl
Oxalate
mg/dl
Phosphorus
mg/dl
Magnesium
mg/dl
Normal 1.26±0.21 39.48±0.50 5.720±0.02 2.58±0.03 1.88±0.24 3.24±0.26 1.85±0.19
Control (EG+AC) 1.83±0.12b 48.94±0.57a 18.64±0.04a 6.25±0.25a 3.73±0.28a 5.48±0.29a 2.72±0.13c
Standard Cystone 
(5ml/kg)
0.53±0.01**
*
41.99±0.41**
*
10.82±0.03**
*
2.87±0.10*** 1.99±0.21*** 3.07±0.29*** 1.73±0.20**
EPU 200mg/kg 1.31±0.08* 51.69±0.50** 10.26±0.08**
*
4.517±0.20**
*
2.65±0.31* 4.16±0.46* 1.79±0.18**
EPU 400mg/kg 0.81±0.01**
*
39.28±0.49** 8.55±0.03*** 2.99±0.10*** 1.66±0.23*** 3.36±0.19*** 1.58±0.20**
*
Table.no.1: Effect of ethanolic extract of Phyllanthus urinaria on serum parameters against EG and AC induced urolithiasis
All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of Dunnett’s test, *p<0.05, **p<0.01, ***p<0.001 as compared to
control and ap<0.001,bp<0.01 and p<0.05 as when compared to normal.
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Fig.no.1: Effect of ethanolic extract of Phyllanthus urinaria on serum creatinine 
against EG and AC induced urolithiasis
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of
Dunnett’s test, *p<0.05, ***p<0.001 as compared to control and bp<0.01 as when compared to
normal.
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Fig.no.2: Effect of ethanolic extract of Phyllanthus urinaria on serum urea against 
EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of
Dunnett’s test, **p<0.01, ***p<0.001 as compared to control and ap<0.001as when compared
to normal.
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Fig.no.3: Effect of ethanolic extract of Phyllanthus urinaria on serum uric acid 
against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of
Dunnett’s test, ***p<0.001 as compared to control and ap<0.001, as when compared to normal.
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Fig.no.4: Effect of ethanolic extract of Phyllanthus urinaria on serum calcium 
against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of
Dunnett’s test, ***p<0.001 as compared to control and ap<0.001 as when compared to normal.
Department of pharmacology Page 53
Fig.no.5: Effect of ethanolic extract of Phyllanthus urinaria on serum oxalate 
against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of
Dunnett’s test, *p<0.05, ***p<0.001 as compared to control and ap<0.001 as when compared to
normal.
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Fig.no.6: Effect of ethanolic extract of Phyllanthus urinaria on serum phosphorus 
against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of
Dunnett’s test, *p<0.05, ***p<0.001 as compared to control and ap<0.001 as when compared to
normal.
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Fig.no.7: Effect of ethanolic extract of Phyllanthus urinaria on serum creatinine 
against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of
Dunnett’s test,**p<0.01, ***p<0.001 as compared to control and cp<0.05 as when compared to
normal.
Department of pharmacology Page 56
Effect  of  ethanolic  extract  of  Phyllanthus  urinaria on  urine  biochemical
parameters against EG and AC induced urolithiasis.
Urinary Creatinine:
Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.001) in urine creatinine concentration compared to normal one. Standrad cystone
5ml/kg causes  significant  reduction (p<0.01) in urine creatinine concentration when
compared  to  EG  and  AC  alone  treated  group.   Pretreatment  with  EPU  200  and
400mg/kg causes significant reduction (not significant and p<0.001) in urine creatinine
concentration when compared to EG and AC alone treated group.
Urinary urea
Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.001)  in  urine  urea  concentration  compared  to  normal  one.  Standrad  cystone
5ml/kg  causes  significant  reduction  (p<0.001)  in  urine  urea  concentration  when
compared  to  EG  and  AC  alone  treated  group.   Pretreatment  with  EPU  200  and
400mg/kg  causes  significant  reduction  (p<0.01  and  p<0.001)  in  urine  urea
concentration when compared to EG and AC alone treated group.
Urinary Calcium
Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.001) in urine calcium concentration compared to normal one. Standrad cystone
5ml/kg  causes  significant  reduction  (p<0.001)  in  urine  calcium concentration  when
compared  to  EG  and  AC  alone  treated  group.   Pretreatment  with  EPU  200  and
400mg/kg  causes  significant  reduction  (p<0.05  and  p<0.001)  in  urine  calcium
concentration when compared to EG and AC alone treated group.
Department of pharmacology Page 57
Urinary Oxalate
Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.001) in urine oxalate concentration compared to normal  one.  Standrad cystone
5ml/kg  causes  significant  reduction  (p<0.001)  in  urine  oxalate  concentration  when
compared  to  EG  and  AC  alone  treated  group.   Pretreatment  with  EPU  200  and
400mg/kg  causes  significant  reduction  (p<0.001  and  p<0.001)  in  urine  oxalate
concentration when compared to EG and AC alone treated group.
Urinary Phosphorus
Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.001) in urine phosphorus concentration compared to normal one. Standrad cystone
5ml/kg causes significant reduction (p<0.001) in urine phosphorus concentration when
compared  to  EG  and  AC  alone  treated  group.   Pretreatment  with  EPU  200  and
400mg/kg  causes  significant  reduction  (p<0.05  and  p<0.001)  in  urine  phosphorus
concentration when compared to EG and AC alone treated group.
Urinary Magnesium
Administration of EG and AC (0.75% and 2%) for 10 days caused significant increased
(p<0.001) in urine magnesium concentration compared to normal one. Standrad cystone
5ml/kg causes significant reduction (p<0.001) in urine magnesium concentration when
compared  to  EG  and  AC  alone  treated  group.   Pretreatment  with  EPU  200  and
400mg/kg  causes  significant  reduction  (p<0.05  and  p<0.001)  in  urine  magnesium
concentration when compared to EG and AC alone treated group.
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Table.no.2: Effect of ethanolic extract of Phyllanthus urinaria on urine biochemical parameters against EG and AC induced urolithiasis.
Treatment group
Urine Biochemical Parameters
Creatinine 
mg/dl
Urea
mg/dl
Uric Acid
mg/dl
Calcium
mg/dl
Oxalate
mg/dl
Phosphorus
mg/dl
Magnesium
mg/dl
Normal 0.28±0.02 58.94±2.35 2.31±0.16 10.65±0.83 6.81±0.41 3.195±0.01 4.77±0.37
Control (EG+AC) 0.59±0.05a 88.82±3.19a 6.01±0.28a 18.49±1.03a 15.65±1.22a 9.093±0.46a 1.94±0.01a
Standard Cystone 
(5ml/kg)
0.40±0.01** 53.05±2.10**
*
2.99±0.36*** 11.62±0.72**
*
7.03±0.46*** 4.758±0.27**
*
4.36±0.48**
*
EPU 200mg/kg 0.49±0.04ns 73.48±3.53** 3.56±0.25*** 14.37±0.98* 7.60±0.57*** 7.58±0.45* 3.51±0.48*
EPU 400mg/kg 0.45±0.02* 64.88±2.10**
*
3.44±0.23*** 12.81±0.88**
*
7.37±1.01*** 5.94±0.31*** 4.65±0.41**
*
All  the  values  are  Mean±SEM, n=6,  ns= not  significant,  One  way ANOVA followed  by  multiple  comparision  of  Dunnett’s  test,  *p<0.05,  **p<0.01,
***p<0.001 as compared to control and ap<0.001, as when compared to normal.
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Fig.no.8: Effect of ethanolic extract of Phyllanthus urinaria on urine creatinine 
parameters against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparison of
Dunnett’s test, *p<0.05, **p<0.01 as compared to control and ap<0.001, as when compared to
normal.
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Fig.no.9: Effect of ethanolic extract of Phyllanthus urinaria on urine urea 
parameters against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparison of
Dunnett’s test,  **p<0.01, ***p<0.001 as compared to control and ap<0.001, as when compared
to normal.
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Fig.no.10: Effect of ethanolic extract of Phyllanthus urinaria on urine uric aicd
parameters against EG and AC induced urolithiasis.
Urine Uric acid
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparison of
Dunnett’s test, ***p<0.001 as compared to control and ap<0.001, as when compared to normal.
Department of pharmacology Page 62
Fig.no.11: Effect of ethanolic extract of Phyllanthus urinaria on urine calcium
parameters against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparison of
Dunnett’s test, *p<0.05, ***p<0.001 as compared to control and ap<0.001, as when compared
to normal.
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Fig.no.12: Effect of ethanolic extract of Phyllanthus urinaria on urine oxalate
parameters against EG and AC induced urolithiasis.
Urine oxalate
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparison of
Dunnett’s test, ***p<0.001 as compared to control and ap<0.001, as when compared to normal.
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Fig.no.13: Effect of ethanolic extract of Phyllanthus urinaria on urine phosphorus
parameters against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparison of
Dunnett’s test, *p<0.05, ***p<0.001 as compared to control and ap<0.001, as when compared
to normal.
Department of pharmacology Page 65
Fig.no.14: Effect of ethanolic extract of Phyllanthus urinaria on urine magnesium
parameters against EG and AC induced urolithiasis.
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All the values are Mean±SEM, n=6, One way ANOVA followed by multiple comparision of
Dunnett’s test, *p<0.05, ***p<0.001 as compared to control and ap<0.001, as when compared
to normal.
Department of pharmacology Page 66
Effect of ethanolic extract of Phyllanthus urinaria on LPO (kidney enzyme) 
parameters against EG and AC induced urolithiasis.
Oxidative stress 
In-vivo LPO In control animals, EG/AC induced lithogenesis produced a significant
enhancement in the renal MDA levels (p<0.001) respectively, when compared to the
normal  group.  After  treatment  with  standard  cystone  5ml/kg  and  EPU  200  and
400mg/kg  significant  (P<0.001) reduction in the kidney MDA levels was observed  in
the treated groups, when compared  to their respective control groups. 
Catalase levels of the kidney were significantly (p<0.001) decreased in the control 
groups on EG/AC administration for 10 days, when compared to the normal group. On 
treatment with Standrad cystone and EPU 200 and 400mg/kg (p<0.001), a significant 
rise in the renal catalase levels was observed in treated groups (Table 3).
GSH levels of the kidney were significantly (p<0.001) decreased in the control groups 
on EG/AC administration for 10 days, when compared to the normal group. On 
treatment with Standrad cystone  (p<0.01) and EPU 200 (p<0.05) and 400mg/kg 
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(p<0.01), a significant rise in the renal catalase levels was observed in treated groups 
(Table 3)
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Table.no.3: Effect of ethanolic extract of Phyllanthus urinaria on antioxidant (kidney enzyme) parameters against EG and AC induced 
urolithiasis.
All  the  values  are Mean±SEM, n=6, ns=
not significant, One way ANOVA followed by multiple comparision of Dunnett’s test, *p<0.05, **p<0.01, ***p<0.001 as compared to control and ap<0.001,
as when compared to normal.
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Treatment group
Invivo Antioxidant parameters
CATALASA 
µm/mg tissue
GSH
µm/mg tissue
LPO
µm of /H2O2/mg 
tissue
Normal 29.95±0.72 14.97±0.67 133.1±3.60
Control (EG+AC) 16.73±0.74a 7.970±0.83a 219.8±4.65a
Standard Cystone (5ml/kg) 26.19±1.25*** 12.80±0.68** 152.3±3.29***
EPU 200mg/kg 23.29±0.92*** 9.74±1.04* 176.7±5.05***
EPU 400mg/kg 26.00±0.56*** 12.68±0.85** 164.9±5.59***
Fig.no.16: Effect of ethanolic extract of Phyllanthus urinaria on Catalase (kidney 
enzyme) parameters against EG and AC induced urolithiasis.
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All  the values  are  Mean±SEM, n=6,  One way ANOVA followed by multiple  comparison  of
Dunnett’s test, ***p<0.001 as compared to control and ap<0.001, as when compared to normal.
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Fig.no.17: Effect of ethanolic extract of Phyllanthus urinaria on Catalase (kidney 
enzyme) parameters against EG and AC induced urolithiasis.
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All the values are Mean±SEM, One way ANOVA followed by multiple comparision of Dunnett’s
test, *p<0.05,  ***p<0.001 as compared to control and ap<0.001, as when compared to normal.
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Fig.no.18: Effect of ethanolic extract of Phyllanthus urinaria on Lipidperoxide 
(kidney enzyme) parameters against EG and AC induced urolithiasis.
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All the values are Mean±SEM, One way ANOVA followed by multiple comparision of Dunnett’s
test, ***p<0.001 as compared to control and ap<0.001, as when compared to normal.
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HISTOPATHOLOGY OF KIDNEY
Normal rats kidney showing normal cellular structure.
The histopathology of kidney samples of rats treated with EG+AC (0.75 and 2%) showed
loss of  normal architecture with presence of  crystalline structure in dilated collecting
tubules. The same section when viewed under polarising microscope revealed presence of
white chalky coloured calcium oxalate crystals in several tubules and glomeruli. These
groups also showed congestion of  intersitum and inflammation of  the pelvic calyceal
systems.
The histopathology of kidney samples of rats treated with standard drug cystone 5ml/kg
and EG+AC for 10 days showed normal architecture of the kidney.
The histopathology of kidney samples of rats treated with EUP 200mg/kg and EG+AC
for 10 days showed mild colloidal cast inside tubules and EUP 400mg/kg showed cloudy
changes and congestion of thes glomeruli. However the architecture of kidney approved
almost normal.
Fig.no.19: Histopathology of kidney
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 A: Normal group, B: EG+AC group:, C Standard (Cystone 5ml/kg) group,  D group EPU 
200mg/kg, E group EPU 400mg/kg,
                                         7.DISCUSSION 
Urinary stone disease is a common, painful and expensive medical condition80. Though
extracorporeal shock wave lithotripsy has facilitated the stone removal and reduced the
morbidity associated with urinary stone, recurrence is common81. Several experimental
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and  clinical  studies  on  some  of  the  plants  used  in  the  Indian  traditional  system  of
medicine proved their efficacy in the management of renal stone disease. Therefore, it is
advisable to evaluate plants used in the traditional medicine to treat kidney stone disease
for Antiurolithiatic activity, which might be also useful in reducing stone recurrence rate.
Rats are commonly used to study the pathogenesis of human CaOx kidney stone disease,
as Ox metabolism is regarded almost similar in rats and humans82. Ingestion of EG/AC
has  been  found  to  be  a  reliable  inducer  of  Ox  lithiasis  in  rats.  EG is  converted  to
endogenous  oxalic  acid  by the  liver  enzyme glycolate  oxidase  [19]  and  AC induces
urinary acidification, is supposed to upset the enzyme sorting mechanism in the tubular
cells in the kidney83, thus favours adhesion and retention of CaOx particles within the
renal tubules.
Hence,  in  the  present  study,  EG/AC  in  drinking  water  was  employed  to  induce
hyperoxaluria in rats. Urinary supersaturation in relation to stone forming constituents,
mainly urinary oxalate is important in renal calculi formation84,  as urinary oxalic acid
complexes with calcium and forms insoluble CaOx crystals85. Enhanced deposition and
urinary excretion of calcium and oxalate in the preventive and curative control  group
animals indicate that administration of EG/AC induced hyperoxaluria. An increase in the
kidney weight and enhanced urinary creatinine excretion in the control group animals
also substantiated these results.
On  administration  of  EPU,  the  dose-dependent  reduction  in  calcium  and  oxalate
deposition  in  the  kidneys  and  their  urinary  excretion  in  control  groups  implies  the
potential of EPU. in preventing the formation and dissolving the preformed CaOx stones.
On  treatment  with  the  extract  and  standard  cystone,  the  significant  reduction  in  the
elevated urinary creatinine, urea, uric acid, calcium, phosphorus, oxalate and magnesium
in  the  treated  groups  reflects  the  improvement  in  hyperoxaluria  induced  renal
impairment. Dissolution of calculi can be achieved by alteration in urinary pH86. If the pH
is 5.0 or below, the stones likely to form are of uric acid type, if 5.0-6.5, calcium oxalate
type and if above 7 indicates crystals of magnesium ammonium phosphate. In the present
study,  a  decrease in the normal urine pH of 7.0-7.5 to 5.5-6.0 in the control  groups,
indicates hyperoxaluria induced CaOx stone formation. In the treated groups, EPU and
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cystone 5ml/kg administration restored the pH to 6.5-7.5, supporting the decrease in the
deposition and excretion of calcium and oxalate.
Mucoproteins  have  significant  affinity  for  CaOx  surface  and  promote  the  growth  of
crystals and cement them.87 Flavonoids act by disintegrating the mucoprotiens, thereby
prevent  calcium  and  oxalate  deposition  and  excretion88.  In  the  present  study  also,
preliminary phytochemical screening of EPU revealed the presence of flavonoids. Thus,
in the EPU treated groups, flavonoids might have reduced calcium and oxalate deposition
by pre-coating CaOx crystals and disintegrating the mucoproteins.  The stone forming
effects of EG are also ascribed to its hyperoxaluria induced oxidative damage. Oxalate
has been reported to induce LPO and to cause renal tissue damage. As kidney is rich in
polyunsaturated fatty acids, is susceptible to ROS attack.  89.   Excessive generation of
ROS and/or a reduction in cellular antioxidant levels results in the development of OS. 
MDA is one of the most common by products of ROS induced OS. In the present study,
increased levels of MDA, diminished levels of GSH and catalase in the control groups
indicate that EG/ AC administration promoted extensive generation of ROS. The resultant
ROS  may  have  consumed  GSH  and  catalase  excessively  and  impaired  antioxidant
protection. Thus, the unquenched ROS may have provoked cellular damage and resulted
in enhanced OS, which might have further favoured the accumulation and retention of
oxalate  and  subsequent  deposition  of  CaOx.  Studies  show  that  treatment  with
antioxidants prevents CaOx deposition in the kidney and reduce Ox excretion.  90 Daily
consumption  of  tea  reduced  the  risk  of  kidney  stone  formation  in  women  by  8%.
[Moreover, low concentration of renal cellular glutathione favours LPO and subsequent
retention of calcium and oxalate in the kidneys91.
Health benefits of tea are due to its antioxidant properties of flavonoids 92 which act by
quenching ROS and also by chelating metal ions like iron and copper. Lupeol and betulin
were proposed to act by scavenging oxalate promoted free radicals and enhancing body
antioxidant status, thus reducing oxalate induced renal peroxidative tissue damage. 93 In
the present study, lowered levels of MDA and enhanced levels of antioxidant enzymes,
GSH and catalase  in  the  kidneys  of  the  EPU treated  animals  indicate  attenuation  of
hyperoxaluria induced LPO and oxidative damage. Flavonoids may have minimized ROS
by free radical scavenging and prevented further generation, by metal chelating property,.
Thus, the flavonoid principles of phyllanthus urinaria might have been responsible for the
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inhibition of CaOx crystal aggregation and stone formation. The results support the use of
Phyllanthus  urinaria  plant  as  an  effective  alternative  in  treating  CaOx  urolithiasis.
Disintegration of the mucoproteins and pre-coating of CaOx crystals by antioxidant effect
of  flavonoid principles  may be responsible for  the possible antiurolithiatic activity of
Phyllanthus urinaria. Further studies are necessary to find out the chemical components 
responsible for the antiurolithiatic activity of Phyllanthus urinaria L.
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                                        8. CONCLUSION
In conclusion, the presented data indicate that administration of the EPU plant
to  rats  with  ethylene  glycol/Ammonium chloride  induced  lithiasis  and  prevented  the
formation of urinary stones, supporting folk information regarding antiurolithiatic activity
of the plant. The mechanism underlying this effect is still  unknown, but is apparently
related to diuresis and lowering of urinary concentration of stone forming constituents.
The protective effect against oxalate induced lipid peroxidation may be contributing to
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the recovery of renal damage. These effects could conclude the antiurolithiatic property
of Phyllanthus urinaria.
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                                            9.  SUMMARY
 In the present study, dried powder of Phyllanthus urinaria was subjected to
extraction  using  90%  ethanol  for  the  extraction.  Some  extract  was  reserved  for
preliminary  phytochemical  investigation  and  rest  was  utilized  for  pharmacological
screening.
                The preliminary phytochemical investigation showed the presence of alkaloids,
carbohydrates, glycosides, saponins, and flavonoids.
               The pharmacological screening included evaluation of antiurolithiatic activity
using  0.75% ethylene  glycol/ammonium  chloride  induced  urolithiasis  model  in  male
Wistar albino rats. The kidney stone formation induced in rats, as a result of 10 days
chronic administration of 0.75% and 2% ammonium chloride, was significantly inhibited
by oral administration of EPU.
             Administration of EPU and Cystone 5ml/kg caused significantly increased urine
output and pH of the urine as compared to control (EG and AC) group.
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             Pretreatment with standard cystone 5ml/kg, EPU 200 and 400mg/kg causes
significant reduction in serum creatinine, urea, uric acid, calcium, oxalate, phosphorus
and magnesium concentration when compared to EG and AC alone treated group.
            Pretreatment with standard cystone 5ml/kg, EPU 200 and 400mg/kg causes
significant reduction in urinary creatinine, urea, uric acid, calcium, oxalate, phosphorus
and magnesium concentration when compared to EG and AC alone treated group.
            After treatment with standard cystone 5ml/kg and EPU 200 and 400mg/kg
significant reduction in the kidney MDA levels was observed in the treated groups, when
compared  to their respective control groups. 
              Catalase and GSH levels of the kidney were significantly decreased in the
control  groups on EG/AC administration for  10 days,  when compared  to  the normal
group. On treatment with Standrad cystone and EPU 200 and 400mg/kg a significant rise
in the renal catalase and GSH levels was observed in treated groups.
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